TOI vs. SHLT, PTWO, CANOQ, CCM, HIMS, TDOC, AUNA, LFMD, AIRS, and TBRG
Should you be buying Oncology Institute stock or one of its competitors? The main competitors of Oncology Institute include SHL Telemedicine (SHLT), Pono Capital Two (PTWO), Cano Health (CANOQ), Concord Medical Services (CCM), Hims & Hers Health (HIMS), Teladoc Health (TDOC), Auna (AUNA), LifeMD (LFMD), AirSculpt Technologies (AIRS), and TruBridge (TBRG).
SHL Telemedicine (NASDAQ:SHLT) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, community ranking, valuation, earnings and risk.
In the previous week, Oncology Institute had 1 more articles in the media than SHL Telemedicine. MarketBeat recorded 3 mentions for Oncology Institute and 2 mentions for SHL Telemedicine. SHL Telemedicine's average media sentiment score of 0.51 beat Oncology Institute's score of -0.50 indicating that Oncology Institute is being referred to more favorably in the news media.
SHL Telemedicine has a beta of -0.6, indicating that its share price is 160% less volatile than the S&P 500. Comparatively, Oncology Institute has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.
SHL Telemedicine has higher earnings, but lower revenue than Oncology Institute.
20.1% of SHL Telemedicine shares are held by institutional investors. Comparatively, 36.9% of Oncology Institute shares are held by institutional investors. 9.5% of Oncology Institute shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Oncology Institute received 3 more outperform votes than SHL Telemedicine when rated by MarketBeat users. However, 100.00% of users gave SHL Telemedicine an outperform vote while only 66.67% of users gave Oncology Institute an outperform vote.
SHL Telemedicine currently has a consensus target price of $11.00, suggesting a potential upside of 101.47%. Oncology Institute has a consensus target price of $2.25, suggesting a potential upside of 389.02%. Given SHL Telemedicine's higher possible upside, analysts plainly believe Oncology Institute is more favorable than SHL Telemedicine.
SHL Telemedicine has a net margin of 0.00% compared to SHL Telemedicine's net margin of -20.28%. Oncology Institute's return on equity of 0.00% beat SHL Telemedicine's return on equity.
Summary
Oncology Institute beats SHL Telemedicine on 8 of the 14 factors compared between the two stocks.
Get Oncology Institute News Delivered to You Automatically
Sign up to receive the latest news and ratings for TOI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TOI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncology Institute Competitors List
Related Companies and Tools
